Abstract
Despite increasing rates of COVID-19 vaccination among those living in the United States, there is little known about the prevalence of vaccination among patients with chronic inflammatory skin diseases and if any significant adverse reactions have occurred within these specific groups. The goal of this study was to further analyze these trends. A retrospective analysis was conducted from December 2020 to March 2021 using TriNetX, a national federated, real time database of 69 million records. The prevalence of COVID-19 vaccination among patients with inflammatory skin diseases including psoriasis (Pso), atopic dermatitis (AD), and hidradenitis suppurativa (HS) was calculated.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
